ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES Russian patent published in 2016 - IPC C07K16/22 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry. Disclosed are a human antibody or antigen-binding fragment of the human antibody, which specifically bind and inhibit human angiopoietin-like 4 protein (hANGPTL4). Described are a nucleic acid molecule coding the disclosed antibody or antigen-binding fragment, and an expression vector containing this acid. Described is a method for producing the antibody involving the use of a host cell containing the above expression vector. Besides, described is a pharmaceutical composition containing the disclosed antibody. The invention can be used in treating ANGPTL4-related diseases or disorders, such as hyperlipidemia, hyperlipoproteinemia, dyslipidemia, including hypertriglyceridemia, hypercholesteremia, hyperlipoproteinemia, etc. Further, the anti-hANGPTL4 antibodies can be administered into an individual in need thereof for preventing or treating diseases or disorders, for which disturbance in lipid metabolism represents a risk factor. These diseases or disorders involve cardiovascular diseases, such as atherosclerosis or atherosclerotic heart disease; acute pancreatitis, non-alcoholic fatty liver disease (NASH); diabetes; obesity, etc.

EFFECT: what is presented is a method for preventing or treating a disease or disorder, which can be prevented, relieved, reduced or inhibited by reducing or inhibiting ANGPTL4 activity, involving administering a therapeutically effective amount of the pharmaceutical composition in need thereof.

19 cl, 7 dwg, 18 tbl, 13 ex